Bcl-xL inhibitor

DRUG CLASS:

Bcl-xL inhibitor

News alerts, weekly reports and conference planners

Related drugs:

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	trametinib + dabrafenib + ABT 263 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + ABT 263 Sensitive : C2	trametinib + dabrafenib + ABT 263 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	A-1331852 Sensitive: C3 – Early Trials A-1331852 Sensitive : C3	A-1331852 Sensitive: C3 – Early Trials A-1331852 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ABT 263 Sensitive: C3 – Early Trials ABT 263 Sensitive : C3	ABT 263 Sensitive: C3 – Early Trials ABT 263 Sensitive : C3
BCL2L1 overexpression	Non Small Cell Lung Cancer	BCL2L1 overexpression	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
STRN-ALK rearrangement	Mesothelioma	STRN-ALK rearrangement	Mesothelioma	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib + ABT 263 Sensitive: D – Preclinical trametinib + ABT 263 Sensitive : D	trametinib + ABT 263 Sensitive: D – Preclinical trametinib + ABT 263 Sensitive : D
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D	ABT 263 + ABT-414 Sensitive: D – Preclinical ABT 263 + ABT-414 Sensitive : D
BCL2L2 overexpression	Diffuse Large B Cell Lymphoma	BCL2L2 overexpression	Diffuse Large B Cell Lymphoma	ABT 263 Resistant: D – Preclinical ABT 263 Resistant : D	ABT 263 Resistant: D – Preclinical ABT 263 Resistant : D
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	lapatinib + APG-1252 Sensitive: D – Preclinical lapatinib + APG-1252 Sensitive : D	lapatinib + APG-1252 Sensitive: D – Preclinical lapatinib + APG-1252 Sensitive : D
BCL2L1 overexpression	Gastric Cancer	BCL2L1 overexpression	Gastric Cancer	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D
KRAS G12D	Lung Cancer	KRAS G12D	Lung Cancer	selumetinib + ABT 263 Sensitive: D – Preclinical selumetinib + ABT 263 Sensitive : D	selumetinib + ABT 263 Sensitive: D – Preclinical selumetinib + ABT 263 Sensitive : D
BCL2 overexpression	Multiple Myeloma	BCL2 overexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
MCL1 underexpression	Multiple Myeloma	MCL1 underexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
BCL2L1 underexpression	Multiple Myeloma	BCL2L1 underexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D	ABT 263 + AZD8055 Sensitive: D – Preclinical ABT 263 + AZD8055 Sensitive : D
BCL2L1 overexpression	Pancreatic Cancer	BCL2L1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
CHEK1 overexpression	Pancreatic Cancer	CHEK1 overexpression	Pancreatic Cancer	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D	ACR-368 + ABT 263 Sensitive: D – Preclinical ACR-368 + ABT 263 Sensitive : D
BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer	BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer	AT 101 Sensitive: D – Preclinical AT 101 Sensitive : D	AT 101 Sensitive: D – Preclinical AT 101 Sensitive : D
EGFR L8585R + EGFR T790M + RBM10 G840fs*7	Lung Cancer	EGFR L8585R + EGFR T790M + RBM10 G840fs*7	Lung Cancer	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D
EGFR L858R + RBM10 Q255*	Lung Cancer	EGFR L858R + RBM10 Q255*	Lung Cancer	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D	osimertinib + ABT 263 Sensitive: D – Preclinical osimertinib + ABT 263 Sensitive : D
MCL1 overexpression	Colorectal Cancer	MCL1 overexpression	Colorectal Cancer	APG1244 + MCL1 inhibitor Sensitive: D – Preclinical APG1244 + MCL1 inhibitor Sensitive : D	APG1244 + MCL1 inhibitor Sensitive: D – Preclinical APG1244 + MCL1 inhibitor Sensitive : D
MCL1 overexpression	Colorectal Cancer	MCL1 overexpression	Colorectal Cancer	APG1244 Resistant: D – Preclinical APG1244 Resistant : D	APG1244 Resistant: D – Preclinical APG1244 Resistant : D
BCL2 overexpression	Lung Cancer	BCL2 overexpression	Lung Cancer	gefitinib + ABT 263 Sensitive: D – Preclinical gefitinib + ABT 263 Sensitive : D	gefitinib + ABT 263 Sensitive: D – Preclinical gefitinib + ABT 263 Sensitive : D

Bcl-xL inhibitor

Bcl-xL inhibitor

Associations(36)

Associations
(36)